Abstracts Archive - Page 2255 of 2607 - ACR Meeting Abstracts

Abstract Number: 2688 • 2013 ACR/ARHP Annual Meeting
Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Ronald F. van Vollenhoven³, Stefan Florentinus⁴, Piyalal M. Karunaratne⁵, Hartmut Kupper⁶, Maxime Dougados⁷ and Roy Fleischmann⁸, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³The Karolinska Institute, Stockholm, Sweden, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Adalimumab is usually used in combination with 15-20 mg methotrexate (MTX) weekly in early rheumatoid arthritis (RA). Lower doses of MTX in combination with…
Abstract Number: 2689 • 2013 ACR/ARHP Annual Meeting
Assessing Maintenance Of Remission After Withdrawal Of Etanercept Plus Methotrexate, Methotrexate Alone, Or Placebo In Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study
Paul Emery¹, Wolfgang Spieler², Maria Stopinska-Polaszewska³, Nikolay I Korshunov⁴, Jack Bukowski⁵, Ronald Pedersen⁶, Theresa Williams⁷, Stefanie Gaylord⁷ and Bonnie Vlahos⁷, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ³Family Physicians Specialists Clinic, Torun, Poland, ⁴State Budgetary Healthcare Institution of Yaroslavl Region, Yaroslavl, Russia, ⁵Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: In the PRIZE study patients (pts) with early (mean 6 mos. since symptom onset) moderate-severe rheumatoid arthritis (RA), who achieved remission after open-label treatment…
Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Bruno Fautrel¹, Thao Pham², Jacques Morel³, Toni Alfaiate⁴, Emmanuelle Dernis⁵, Philippe Gaudin⁶, Olivier Brocq⁷, Elisabeth Solau-Gervais⁸, Jean-Marie Berthelot⁹, Jean-Charles Balblanc¹⁰, Xavier Mariette¹¹ and Florence Tubach¹², ¹Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Le Mans Hospital, Le Mans, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Hospital of Princesse Grâce de Monaco, Monaco, France, ⁸Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁹Rheumatology Unit, Nantes University Hospital, Nantes, France, ¹⁰Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹²INSERM, Universite Paris Diderot, Paris, France
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 2692 • 2013 ACR/ARHP Annual Meeting
Evidence That Fat Metaplasia Is a Key Intermediary In The Development Of Sacroiliac Joint Ankylosis Following Repair Of Erosions In Patients With Spondyloarthritis
Walter P. Maksymowych¹, Stephanie Wichuk¹, Praveena Chiowchanwisawakit², Robert GW Lambert³ and Susanne Juhl Pedersen⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Mahidol University, Bangkok, Thailand, ³Radiology, University of Alberta, Edmonton, AB, Canada, ⁴Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Background/Purpose: Fat metaplasia is detected as bright signal on T1W MRI and has been shown to develop after resolution of inflammation in spine and sacroiliac…
Abstract Number: 2693 • 2013 ACR/ARHP Annual Meeting
Proof Of Concept: Enthesitis and New Bone Formation In Spondyloarthritis Are Driven By Mechanical Strain and Stromal Cells
Peggy Jacques¹, Stijn Lambrecht¹, Eveline Verheugen¹, Elin Pauwels², Marleen Verhoye³, Annemie Van der Linden³, George Kollias⁴, Rik J. Lories⁵ and Dirk Elewaut⁶, ¹Dept of Rheumatology, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, ²Dept of Physics and Astronomy, UGCT, Ghent University, Ghent, Belgium, ³Bio-imaging Lab, University of Antwerp, Antwerp, Belgium, ⁴Institute of Immunology, Biomedical Sciences Research Center 'Alexander Fleming', Vari, Greece, ⁵Dept of Development and Regeneration, Laboratory for Skeletal Development and Joint Disorders, KU Leuven, Leuven, Belgium, ⁶Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: Spondyloarthritides (SpA) are characterised by both peripheral and axial arthritis. Hallmarks of peripheral SpA are the development of enthesitis, most typically of the Achilles…
Abstract Number: 2694 • 2013 ACR/ARHP Annual Meeting
HLA-B27 Expression Prevents Tnfα-Induced Inhibition Of Bone Formation in Vitro In IFNγ/Tnfα-Treated Osteoblasts
Eva Yang¹, Grace Kwon¹, Robert A. Colbert² and Gerlinde Layh-Schmitt¹, ¹NIAMS NIH, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: HLA-B27 predisposes to ankylosing spondylitis (AS), an immune-mediated inflammatory disease associated with osteitis, bone loss, and dysregulated bone formation, most notably in the axial…
Abstract Number: 2655 • 2013 ACR/ARHP Annual Meeting
Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Miri Blank¹, Silvia S. Pierangeli², Honorio Torres-Aguilar³ and Yehuda Shoenfeld⁴, ¹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³National Center for Blood Transfusion, Mexico City, Mexico, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel
Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice…
Abstract Number: 2656 • 2013 ACR/ARHP Annual Meeting
Performance Of Prediction Models For Rheumatoid Arthritis Serologic Phenotypes Among Women Using Family History, Genetics and Environmental Factors
Jeffrey A. Sparks¹, Chia-Yen Chen², Xia Jiang³, Linda T. Hiraki⁴, Lars Klareskog⁵, Lars Alfredsson³, Karen H. Costenbader⁶ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Family history (FH) of autoimmunity, genetics, and environmental factors have been associated with RA. The area under the receiver operating characteristic curve (AUC) can…
Abstract Number: 2657 • 2013 ACR/ARHP Annual Meeting
Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Elizabeth V. Arkema¹, Susan Malspeis², Bing Lu³, Linda T. Hiraki⁴, Elizabeth W. Karlson² and Karen H. Costenbader², ¹Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA
Background/Purpose: Smoking and high body mass index (BMI) are risk factors for RA. Both are associated with increased systemic inflammation, with elevated C-reactive protein, interleukin…
Abstract Number: 2658 • 2013 ACR/ARHP Annual Meeting
Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
Seoyoung C. Kim¹, Sebastian Schneeweiss², Robert J. Glynn³, Michael Doherty³, Allison Goldfine⁴ and Daniel H. Solomon^5,6, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Joslin Diabetes Center, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Dipeptidyl peptidase-4 inhibitors (DPP4i), such as linagliptin, saxagliptin, and sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane…
Abstract Number: 2659 • 2013 ACR/ARHP Annual Meeting
Antibodies To Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markers Of Endothelial Dysfunction In First-Degree Relatives Of Patients With Rheumatoid Arthritis: The Studies Of The Etiology Of Rheumatoid Arthritis
Jan M. Hughes-Austin¹, Kendra A. Young², Kevin D. Deane³, Michael H. Weisman⁴, Jane H. Buckner⁵, Ted R. Mikuls⁶, James R. O'Dell⁷, Richard M. Keating⁸, Peter K. Gregersen⁹, Jeremy Sokolove¹⁰, William H. Robinson¹¹, V. Michael Holers¹² and Jill M. Norris², ¹Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology Section, The University of Chicago, Chicago, IL, ⁹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ¹¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Among rheumatoid arthritis (RA) patients, antibodies to citrullinated protein antigens (ACPA) have been detected in atherosclerotic plaques. In particular, antibodies to citrullinated fibrinogen (cit-fib)…
Abstract Number: 2660 • 2013 ACR/ARHP Annual Meeting
Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Ryan W. Gan¹, Kendra A. Young¹, Gary O. Zerbe², M. Kristen Demoruelle³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Michael J. Clare-Salzler¹⁰, Kevin D. Deane³, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and circulating autoantibodies, which can be present in serum years prior to RA diagnosis and can…
Abstract Number: 2661 • 2013 ACR/ARHP Annual Meeting
Physical Activity, Adiposity, and The Risk Of Gout In Women: The Nurses Health Study
Hyon Choi^1,2,3, Lindsay C Burns^4,5, Yuqing Zhang⁶, Sharan Rai¹ and Gary Curhan⁷, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷German Research Center for Environmental Health, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular (CV)-metabolic comorbidities in the US. While the benefits of physical exercise…
Abstract Number: 2662 • 2013 ACR/ARHP Annual Meeting
Quality Of Care Predicts Disease Outcomes Among Patients With Systemic Lupus Erythematosus
Jinoos Yazdany¹, Laura Trupin¹, Patricia P. Katz¹, Gabriela Schmajuk¹ and Edward H. Yelin², ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA
Background/Purpose: Although measures to assess quality of care in systemic lupus erythematosus (SLE) are available, their relationship to long-term disease outcomes is unknown. Using a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].